MG
TENX icon

Michael Gelband’s Tenax Therapeutics TENX Stock Holding History

Michael Gelband’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Buy
184,501
+63,972
+53% +$817K 0.02% 708
2026
Q1 		$1.93M Buy
+120,529
New +$1.63M 0.02% 799

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Michael Gelband's TENX Position: Q2 2026 in Review

Michael Gelband increased its Tenax Therapeutics (TENX) stake by 53% in Q2 2026, buying an estimated $817K and bringing the position to 184,501 shares worth $2.68M. The position accounts for 0.02% of the portfolio, ranked #708.

Michael Gelband first reported a position in TENX in Q1 2026 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Michael Gelband held 184,501 shares of Tenax Therapeutics worth $2.68M as of Q2 2026.
  • Michael Gelband bought 63,972 Tenax Therapeutics shares in Q2 2026, an estimated $817K.
  • Tenax Therapeutics made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #708 holding.
  • Michael Gelband first reported a position in Tenax Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.